AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04907669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief contact intervention
Description: The BCI in this study is a series of structured messages, and messages will be delivered to participants by pushing feeds through WeChat and an iOS/Android application developed for this study. If participants did not use smartphones, messages will be delivered by mobile text messages or by phone calls. Though the final details are yet to be determined by the CBPR study, the investigators expect to structure messages into six components including introduction, greetings for previous complains, mental health promotion, encouragement, and coping strategies, remind of treatment and subsequent visit, and crisis intervention resource.~Noted, the same messages will also be sent to patients' LHSs.
Study NCT05759624 — intervention group
Intervention type: DRUG
Intervention: rhGH
Description: Hormone replacement therapy with rhGH at a dose of 0.025-0.035 mg/kg of body weight per day (or 0.7-1.0 mg/m2 of body surface area per day).
Study NCT06472531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INR101
Description: • 9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT
Study NCT06472531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INR101
Description: * 9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT~* 7±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT
Study NCT05789589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon
Description: Dosing will begin on Day 0 with the loading dose and continue daily through Day 7. Starting on Day 8, dosing will resume with the continuous dose until disease progression or 8 weeks. If there is evidence of antitumor effect at 8 weeks, dosing may continue for up 2 two years.~All doses are taken orally. There are three levels of dosing, including a starting dose and two lower levels of dosing. Participants will start with the starting dose, and in the event of the dose limiting toxicities, the dose will be reduced as described below.~Starting Dose Level: 30 mg twice daily (Loading Dose) or 20 mg once daily (Continuous Dose) Dose Level -1: 15 mg twice daily (Loading Dose) or 10 mg once daily (Continuous Dose) Dose Level -2: 15 mg once daily (Loading Dose) or 5 mg once daily (Continuous Dose)
Study NCT05789589 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Description: Patients will undergo standard of care SRS as per the treating facility's policies.
Study NCT05789589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Two corticosteroid regimens are used depending on the study cohort. Cohorts 1 and 2 will receive the loading dose (LD). Only Cohort 1 will receive the corticosteroid taper (CT).~LD: Oral (8 mg) or IV bolus dose (10 mg) of dexamethasone or 40 to 80 mg of methylprednisolone on the day of SRS CT: Oral 2-4 mg of dexamethasone twice daily for 5 days and then 2-4 mg daily for 5 days at the discretion of the treating physician (concurrent use of a proton pump inhibitor or H2 receptor antagonists are encouraged during the CT).
Study NCT04919824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Submucosal Dissection
Description: Endoscopic submucosal dissection (ESD) is a novel technique for the removal of advanced colonic polyps with high-risk features. ESD is minimally invasive and allows the removal of colonic adenomatous polyp without resorting to surgery. The process of ESD includes marking the lesions selected for removal, followed by submucosal injection of a lifting agent, then circumferential incisions using a specialized knife followed by submucosal dissection of the entire lesion.
Study NCT04919824 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Submucosal Dissection
Description: Endoscopic submucosal dissection (ESD) is a novel technique for the removal of advanced colonic polyps with high-risk features. ESD is minimally invasive and allows the removal of colonic adenomatous polyp without resorting to surgery. The process of ESD includes marking the lesions selected for removal, followed by submucosal injection of a lifting agent, then circumferential incisions using a specialized knife followed by submucosal dissection of the entire lesion.
Study NCT04919824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection
Description: Endoscopic mucosal resection (EMR) is a conventional endoscopic technique commonly used for the resection of superficial neoplastic lesions in the GI tract. EMR carries lower morbidity and mortality compared to surgery.
Study NCT04919824 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Mucosal Resection
Description: Endoscopic mucosal resection (EMR) is a conventional endoscopic technique commonly used for the resection of superficial neoplastic lesions in the GI tract. EMR carries lower morbidity and mortality compared to surgery.
Study NCT06411600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Encorafenib is administered orally at a daily dose of 300 mg, typically in the form of four 75 mg capsules taken together.
Study NCT06411600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is administered intravenously every two weeks at a dose of 500 mg/m².
Study NCT06411600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is administered intravenously every two weeks at a dose of 5 mg/kg.
Study NCT06411600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is administered intravenously every two weeks at a dose of 5 mg/kg.
Study NCT06384001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active MBM
Description: The MBM is designed to be applied for 20 minutes per session daily for two weeks. The recording will instruct participants to close their eyes, connect to the openness of one's minds, and mindfully maintain and deepen the connection through breathing with more openness and awareness. The MBM intervention will include three recordings that gradually take the participant into a more profound meditation practice. Participants will be instructed to listen to Meditation 1 for the first three days of the intervention, then switch to Meditation 2 for days 4-6 and Meditation 3 for the remainder of the 2-week intervention. The participants will be asked to practice meditation for eight weeks (6 weeks after the initial two weeks of MBM practice).
Study NCT06384001 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham MBM
Description: The sham MBM intervention was also recorded. The sham recording will instruct participants to relax and take deep breaths every 3 minutes without the specific mindfulness-based instructions (e.g., practicing mindful attention to the breath in a non-evaluative manner). All other aspects of the sham MBM intervention (e.g., body position, time spent listening to instructions, eyes closed) will match the active MBM.
Study NCT06189157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART19.1
Description: MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells
Study NCT06643364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vision Training Program
Description: Vision Training Programme: A training programme including exercises such as saccadic movements of the eye, spiral movements, converging-diverging exercises, peripheral walking was applied.
Study NCT06643364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Training Program
Description: All athletes continued their routine training programmes planned by the national team coaches for karate sport during the training period.
Study NCT06643364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Training Program
Description: All athletes continued their routine training programmes planned by the national team coaches for karate sport during the training period.
Study NCT05994521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP alone
Description: ERCP with biliary stenting will be performed alone. ERCP is part of standard of care for biliary drainage. An endoscope is advanced to the small intestines and a metal stent is inserted through the tumor instead of bypassing the tumor to effectively drain the biliary system under x-ray guidance.~Management of MGOO will be on a wait-and-see approach, using endoscopic interventions performed only if obstruction is clinically diagnosed
Study NCT05994521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP +ProEUS-GE
Description: ERCP is performed as described above. following the ERCP, the scoped is switched for an echoendoscope which is advanced to the stomach. A stent is then placed between the stomach and the small intestines, creating a connection (ProEUS-GE).
Study NCT05427760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: After changing the diaper, free flow oxygen will be provided to the diaper area for 1 hour with an oxygen cannula placed inside the diaper (oxygen flow is %21 Fio2, 5 L/min)
Study NCT05195918 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: EGCG 300 mg + Nintedanib
Description: Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib
Study NCT05195918 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: EGCG 300 mg + Pirfenidone
Description: Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Pirfenidone
Study NCT05195918 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2 capsules + Nintedanib or Pirfenidone
Description: Dietary Supplement: Placebo Placebo (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib~Drug: Pirfenidone
Study NCT05195918 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: EGCG 600 mg + Nintedanib
Description: Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib
Study NCT05195918 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: EGCG 600 mg + Pirfenidone
Description: Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Pirfenidone
Study NCT05195918 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 4 capsules + Nintedanib or Pirfenidone
Description: Dietary Supplement: Placebo Placebo (4 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib~Drug: Pirfenidone
Study NCT04738890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy
Description: Mindfulness-based cognitive therapy adapted for parents and carers of children with food allergy (MBCT-PCCFA) offered live online by video-conferencing
Study NCT04738890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Continuance as planned of whatever other treatments or interventions the participants were receiving at the time of recruitment.
Study NCT04738890 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Continuance as planned of whatever other treatments or interventions the participants were receiving at the time of recruitment.
Study NCT06140563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anticoagulation dosing
Description: In one arm the normal amount of anticoagulation is administered at the dialysis start, while this is only a quarter of the normal amount of anticoagulation in the other arm.
Study NCT06250647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vitamin K diet
Description: 500mcg of Vitamin K intake provided by the selection of vitamin k rich foods in the menu.
Study NCT06327763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ilioinguinal nerve section
Description: patients operated on by open inguinal hernioplasty with ilioinguinal neurectomy
Study NCT05309460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol Oral Tablet
Description: See Labetalol arm.
Study NCT05309460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NIFEdipine ER
Description: See Nifedipine arm.
Study NCT06180941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulfate.
Description: magnesium sulfate as adjuvant to bupivacaine in supraclavicular brachial plexus block in pediatrics.
Study NCT06180941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine.
Description: clonidine as adjuvant to bupivacaine in supraclavicular brachial plexus block in pediatrics.
Study NCT05719623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CUEVAS MEDEK EXERCISES
Description: stretchings/strengthening
Study NCT05719623 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: BALANCE AND POSTURAL
Description: BALANCE AND POSTURAL
Study NCT05287516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast meal
Description: A meal consisting of breakfast biscuits and water.
Study NCT05287516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast meal
Description: A meal consisting of breakfast biscuits and water.
Study NCT05510635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interactive bibliotherapy
Description: The researcher selected two picture books whose central issues are about the common emotional distress of adolescents with cancer, that is, negative emotion coping, and self-worth. The researcher will read the story to the participant and then use the interview guideline to discuss it with him or her one by one. The interview guideline for interactive bibliotherapy is listed according to the mechanism of bibliotherapy, including identification, catharsis, and insight, and additional questions leading a reader to think deeply.
Study NCT05510635 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reading bibliotherapy
Description: The researcher selected two picture books whose central issues are about the common emotional distress of adolescents with cancer, that is, negative emotion coping, and self-worth. The participant can take 20 to 25 minutes to read the story. No one can bother the participant during the intervention.
Study NCT05983120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Educate the patients who suffer from Type 2 Diabetes Mellitus
Study NCT05202990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation by Stool capsules
Description: After colon cleansing using PolyEthylen glycol, the patient will have a colonoscopy under general anaesthesia.~The patient will then receive orally FMT (frozen stools capsules prepared from healthy donor feces).
Study NCT05202990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation by Intra-rectal enemas
Description: After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anaesthesia.~The patient will then receive first FMT (frozen preparation of stools) by infusion in caecum during colonoscopy and the second and third doses by enemas.
Study NCT05413369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/Lixisenatide
Description: solution, by subcutaneous injection
Study NCT05413369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDegAsp
Description: solution, by subcutaneous injection
Study NCT05492812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedation and Nursing Management in EEG Recording in Children
Description: Evaluation of the effect of sedative agents applied during EEG recording in children
Study NCT05413369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Tablet, orally
Study NCT05413369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablet, orally
Study NCT05413369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: Tablet, orally
Study NCT05413369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Tablet, orally
Study NCT05956158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Treatment
Description: This treatment is designed to help participants make changes to behavior patterns and thoughts that contribute to insomnia.
Study NCT05956158 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Education Treatment
Description: This treatment is designed to help participants understand the relationships among sleep, pain, and Crohn's disease and to make changes to insomnia-related behaviors.
Study NCT06354998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational mRNA-1273.815
Description: Sterile solution for injection
Study NCT06354998 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Spikevax Vaccine
Description: Commercially available formulation
Study NCT05346211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin Supplementation
Study NCT06499168 — intervention group
Intervention type: DRUG
Intervention: neoadjuvant chemotherapy: anthracycline based chemotherapy and taxans before surgery
Description: In locally advanced breast cancer patients who will receive neoadjuvant chemotherapy formalin fixed paraffin embedded tissue specimen of the baseline TCNB of locally advanced breast cancer will be obtained from pathology laboratory, Pathology Department, Assiut University.~* Histological diagnosis of H\&E stained sections will be confirmed.~* Immunohistochemical staining for CD10 .~* Baseline clinicopathological features of patients who will receive neoadjuvant chemotherapy will be collected from patients' records.~* Correlation between CD10 expression and the baseline clinicopathological features with the response to neoadjuvant chemotherapy.
Study NCT05010512 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses used as indicated
Study NCT05010512 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Kalifilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses used as indicated
Study NCT06483815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Culture, İsolation
Description: Data on patient demographics, clinical conditions, and fungal infection positivity rates were extracted from hospital records. Fungal positivity rates were calculated based on laboratory results and presented as percentages. Statistical analyses were performed using the Chi-Square test, and p-values were reported.
Study NCT04958681 — intervention group
Intervention type: OTHER
Intervention: exercise
Description: The participants were subsequently asked whether the pandemic had altered their physical activity status and rate the severity of reduction in mobility level compared to the period before the Covid-19 with the following options: none, 0; mild, 1; moderate, 2; severe, 3. Then, the participants were also asked whether they perform a physical exercise in a home setting. We recorded regular outdoor physical activity and home-based exercises (only after the pandemic) as a dichotomous variable (yes or no). The number of physical activity days per week was also obtained.
Study NCT02389569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adhesive system
Description: Etch-and-rinse and Self-etch adhesive system will be applied in volunteers that received different types of restoration protocol.
Study NCT02389569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration protocol
Description: Volunteers will be treated by two types of protocol restoration : 1) Biosilicate (powder) or 2) Control (without Biosilicate). In sequence, adhesive (self-etch or etch and rinse) and composite resin will be used for restoration.
Study NCT05492812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloral Hydrate
Description: Chloral Hydrate
Study NCT05492812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Description: Hydroxyzine
Study NCT05492812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin
Study NCT05435222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Male-specific psychotherapeutic program (MSPP)
Description: The MSPP for MDD is designed to be used for the acute treatment of depression in men in 18 sessions over a period of 18 weeks. Therapy is delivered weekly with homework bridging every session. Central CBT elements (e.g. behavioral activation, cognitive restructuring) will be retained in MSPP. During implementation of typical CBT techniques, masculine role norms will be considered. One underlying topic will be the potential of multiple masculinities to coexist, being fluid and relational within one man, emphasizing positive aspects of masculinities compatible with psychotherapy for MDD.
Study NCT05435222 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive beahvioral therapy (CBT)
Description: This intervention consists of 18 sessions of manualized, standard cognitive behavioral therapy for major depression. Therapy is delivered weekly with homework bridging every session.